News

To be launched in Germany, Italy, the UK, Netherlands, Belgium and Luxembourg, Remsima is authorised for the treatment of patients with Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing

The company said that TRPH 011 binds and neutralizes VEGFR-2/KDR and TIE 2 receptors simultaneously, resulting in sustained inhibition of tumor growth and angiogenesis. Angiogenesis is the formation

The proposed plan follows a pre-investigational new drug (IND) submission feedback from the US Food and Drug Administration (FDA), which provided guidance on the clinical plan, manufacturing approach,

The trial evaluated the safety, tolerability and pharmacokinetics of OBE001 and betamethasone, a corticosteroid, when co-administered to healthy non-pregnant women. Betamethasone is administered to prevent respiratory distress syndrome

At present, there is no approved antidote to treat these patients and andexanet alfa has the potential to become the first approved universal antidote for Factor Xa inhibitors

The drug is being developed for the treatment of patients with relapsed/refractory and frontline intermediate or high-risk AML and is currently been evaluated in multiple Phase II clinical

Kyprolis is a product of Amgen’s subsidiary Onyx Pharmaceuticals, which holds global development and commercialization rights to the product, excluding Japan. Onyx Pharmaceuticals president Pablo Cagnoni said: "Achieving

The new indication for Eylea includes macular edema following branch retinal vein occlusion (BRVO) in addition to the previously-approved indication of macular edema secondary to central retinal vein

Acceliant platforms offer smooth execution of clinical data management activities such as database design, UAT and several report formats for business intelligence. These platforms give Lupin a collaborative